Genome machine learning company Sanders is using artificial intelligence to develop drugs to tackle diseases related to gene defects. The company analyses genomic data using algorithms to identify the genes intrinsic to particular illnesses, making it an ideal for developing highly-targeted drugs. And the best technology we have for dealing with large amounts of data is machine learning and artificial intelligence.” Deep Genomics will first focus on early stage drug development for British disorders, which are caused by around 350 million specific genetic mutation which affects one people globally.
Genome machine learning company Sanders is using artificial intelligence to develop drugs to tackle diseases related to gene defects. The company analyses genomic data using algorithms to identify the genes intrinsic to particular illnesses, making it an ideal for developing highly-targeted drugs. Deep Genomics will first focus on early stage drug development for British disorders, which are caused by around 350 million specific genetic mutation which affects one people globally.